thioridazine has been researched along with Disease Models, Animal in 23 studies
Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The present study investigated the effect of the dopamine receptor antagonist thioridazine on murine breast cancer." | 7.81 | Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model. ( Guo, F; He, S; Shen, G; Wang, Y; Ye, T; Yin, T, 2015) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 7.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| "Crotamine is a cationic polypeptide composed by 42 amino acid residues with several pharmacological and biological properties, including the selective ability to enter and kill actively proliferating tumour cells, which led us to propose its use as a theranostic agent for cancer therapy." | 5.56 | In vivo effects of the association of the psychoactive phenotiazine thioridazine on antitumor activity and hind limb paralysis induced by the native polypeptide crotamine. ( Campeiro, JD; Godinho, RO; Hayashi, MAF; Oliveira, EB; Papa, GB; Porta, LC; Rodrigues, T, 2020) |
| "Further, a murine model of latent tuberculosis was used and the standard 9-month isoniazid and 4-month rifampicin regimen along with thioridazine as an adjunct drug were evaluated." | 5.40 | Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. ( Sharma, S; Singh, A, 2014) |
| " The present study investigated the effect of the dopamine receptor antagonist thioridazine on murine breast cancer." | 3.81 | Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model. ( Guo, F; He, S; Shen, G; Wang, Y; Ye, T; Yin, T, 2015) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 3.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| " Muscle rigidity was assessed quantitatively and objectively as increases in electromyographic (EMG) activity (muscle rigidity) in the hindlimb muscles of the rat following subcutaneous administration of haloperidol, fluphenazine and thioridazine." | 3.71 | An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. ( Crocker, AD; Hemsley, KM, 2001) |
| "Crotamine is a cationic polypeptide composed by 42 amino acid residues with several pharmacological and biological properties, including the selective ability to enter and kill actively proliferating tumour cells, which led us to propose its use as a theranostic agent for cancer therapy." | 1.56 | In vivo effects of the association of the psychoactive phenotiazine thioridazine on antitumor activity and hind limb paralysis induced by the native polypeptide crotamine. ( Campeiro, JD; Godinho, RO; Hayashi, MAF; Oliveira, EB; Papa, GB; Porta, LC; Rodrigues, T, 2020) |
| "To investigate the efficacy of conservative systemic treatment with dicloxacillin (DCX) in combination with TDZ (DCX+TDZ), compared to DCX alone, against early APVGI caused by methicillin-sensitive Staphylococcus aureus (MSSA) in a porcine model." | 1.46 | Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity. ( Andersen, TE; Behr-Rasmussen, C; Grønnemose, RB; Klein, K; Klitgaard, JK; Kolmos, HJ; Lindholt, JS; Stenger, M, 2017) |
| " Whereas free thioridazine was highly toxic in both cells and zebrafish embryos, after encapsulation in nanoparticles no toxicity was detected." | 1.43 | Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish. ( Anes, E; Bogoeva, V; Fenaroli, F; Griffiths, G; Hildahl, J; Kalluru, R; Pires, D; Speth, M; Vibe, CB; Wilson, SR, 2016) |
| " In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis." | 1.40 | Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis. ( Dutta, NK; Karakousis, PC; Pinn, ML, 2014) |
| "Further, a murine model of latent tuberculosis was used and the standard 9-month isoniazid and 4-month rifampicin regimen along with thioridazine as an adjunct drug were evaluated." | 1.40 | Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. ( Sharma, S; Singh, A, 2014) |
| "Thioridazine treatment resulted in a significant reduction of colony-forming-units of the susceptible (-4." | 1.36 | The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. ( Aguilar, D; Amaral, L; Boeree, MJ; Hernandez-Pando, R; Magis-Escurra, C; Orozco, H; van Ingen, J; van Soolingen, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.70) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Cragnaz, L | 1 |
| Spinelli, G | 1 |
| De Conti, L | 1 |
| Bureau, EA | 1 |
| Brownlees, J | 1 |
| Feiguin, F | 1 |
| Romano, V | 1 |
| Skoko, N | 1 |
| Klima, R | 1 |
| Kettleborough, CA | 1 |
| Baralle, FE | 1 |
| Baralle, M | 1 |
| Mendonça, AAS | 1 |
| Gonçalves-Santos, E | 1 |
| Souza-Silva, TG | 1 |
| González-Lozano, KJ | 1 |
| Caldas, IS | 1 |
| Gonçalves, RV | 1 |
| Diniz, LF | 1 |
| Novaes, RD | 1 |
| Porta, LC | 1 |
| Campeiro, JD | 1 |
| Papa, GB | 1 |
| Oliveira, EB | 1 |
| Godinho, RO | 1 |
| Rodrigues, T | 1 |
| Hayashi, MAF | 1 |
| Dutta, NK | 2 |
| Pinn, ML | 2 |
| Karakousis, PC | 2 |
| Poulsen, MØ | 1 |
| Schøler, L | 1 |
| Nielsen, A | 1 |
| Skov, MN | 1 |
| Kolmos, HJ | 3 |
| Kallipolitis, BH | 1 |
| Olsen, A | 1 |
| Klitgaard, JK | 3 |
| Singh, A | 1 |
| Sharma, S | 1 |
| de Knegt, GJ | 1 |
| ten Kate, MT | 1 |
| van Soolingen, D | 2 |
| Aarnoutse, R | 1 |
| Boeree, MJ | 2 |
| Bakker-Woudenberg, IA | 1 |
| de Steenwinkel, JE | 1 |
| Yin, T | 1 |
| He, S | 1 |
| Shen, G | 1 |
| Ye, T | 1 |
| Guo, F | 1 |
| Wang, Y | 1 |
| Stenger, M | 2 |
| Hendel, K | 1 |
| Bollen, P | 1 |
| Licht, PB | 1 |
| Vibe, CB | 1 |
| Fenaroli, F | 1 |
| Pires, D | 1 |
| Wilson, SR | 1 |
| Bogoeva, V | 1 |
| Kalluru, R | 1 |
| Speth, M | 1 |
| Anes, E | 1 |
| Griffiths, G | 1 |
| Hildahl, J | 1 |
| Seredenina, T | 1 |
| Nayernia, Z | 1 |
| Sorce, S | 1 |
| Maghzal, GJ | 1 |
| Filippova, A | 1 |
| Ling, SC | 1 |
| Basset, O | 1 |
| Plastre, O | 1 |
| Daali, Y | 1 |
| Rushing, EJ | 1 |
| Giordana, MT | 1 |
| Cleveland, DW | 1 |
| Aguzzi, A | 1 |
| Stocker, R | 1 |
| Krause, KH | 1 |
| Jaquet, V | 1 |
| Behr-Rasmussen, C | 1 |
| Klein, K | 1 |
| Grønnemose, RB | 1 |
| Andersen, TE | 1 |
| Lindholt, JS | 1 |
| Hernandez-Pando, R | 1 |
| Orozco, H | 1 |
| Aguilar, D | 1 |
| Magis-Escurra, C | 1 |
| Amaral, L | 1 |
| van Ingen, J | 1 |
| Lo Presti, MS | 1 |
| Rivarola, HW | 2 |
| Bustamante, JM | 2 |
| Fernández, AR | 2 |
| Enders, JE | 2 |
| Fretes, R | 1 |
| Gea, S | 1 |
| Paglini-Oliva, PA | 1 |
| Shiotani, M | 1 |
| Harada, T | 1 |
| Abe, J | 1 |
| Sawada, Y | 1 |
| Hashimoto, K | 1 |
| Hamada, Y | 1 |
| Horii, I | 1 |
| Presti, MS | 1 |
| Fretes, RE | 1 |
| Paglini-Oliva, P | 1 |
| Crocker, AD | 1 |
| Hemsley, KM | 1 |
| Kadar, T | 1 |
| Fishbeine, E | 1 |
| Meshulam, Y | 1 |
| Sahar, R | 1 |
| Chapman, S | 1 |
| Liani, H | 1 |
| Barness, I | 1 |
| Amir, A | 1 |
| Sayers, AC | 1 |
| Bürki, HR | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Klawans, HL | 1 |
| Carvey, P | 1 |
| Tanner, CM | 1 |
| Goetz, CG | 1 |
23 other studies available for thioridazine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance.
Topics: Amyotrophic Lateral Sclerosis; Animals; Autophagy; Cell Line; Disease Models, Animal; DNA-Binding Pr | 2021 |
Thioridazine aggravates skeletal myositis, systemic and liver inflammation in Trypanosoma cruzi-infected and benznidazole-treated mice.
Topics: Acetylglucosaminidase; Animals; Chagas Disease; Cytokines; Disease Models, Animal; Drug Combinations | 2020 |
In vivo effects of the association of the psychoactive phenotiazine thioridazine on antitumor activity and hind limb paralysis induced by the native polypeptide crotamine.
Topics: Animals; Antineoplastic Agents; Crotalid Venoms; Disease Models, Animal; Lower Extremity; Mice; Para | 2020 |
Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine tuberculosis.
Topics: Animals; Antipsychotic Agents; Antitubercular Agents; Disease Models, Animal; Drug Repositioning; Dr | 2014 |
Combination therapy with thioridazine and dicloxacillin combats meticillin-resistant Staphylococcus aureus infection in Caenorhabditis elegans.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Caenorhabditis elegans; Dicloxacillin; Disease Model | 2014 |
Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Isoniazid | 2014 |
Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relat | 2014 |
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combi | 2014 |
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; | 2015 |
Assessments of Thioridazine as a Helper Compound to Dicloxacillin against Methicillin-Resistant Staphylococcus aureus: In Vivo Trials in a Mouse Peritonitis Model.
Topics: Animals; Anti-Bacterial Agents; Dicloxacillin; Disease Models, Animal; Doublecortin Protein; Female; | 2015 |
Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.
Topics: Animals; Antitubercular Agents; Cell Survival; Cells, Cultured; Disease Models, Animal; Drug Therapy | 2016 |
Evaluation of NADPH oxidases as drug targets in a mouse model of familial amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; Female; Gene Expression | 2016 |
Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity.
Topics: Animals; Body Temperature; Body Weight; Dicloxacillin; Disease Models, Animal; Drug Synergism; Femal | 2017 |
The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis.
Topics: Animals; Antipsychotic Agents; Antitubercular Agents; Disease Models, Animal; Drug Resistance, Bacte | 2010 |
Thioridazine treatment prevents cardiopathy in Trypanosoma cruzi infected mice.
Topics: Animals; Antibodies, Protozoan; Chagas Cardiomyopathy; Chagas Disease; Disease Models, Animal; Elect | 2004 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; | 2005 |
Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease; Disease Models, Animal; Drug Evalua | 2007 |
An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.
Topics: Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Rel | 2001 |
Treatment of skin injuries induced by sulfur mustard with calmodulin antagonists, using the pig model.
Topics: Administration, Topical; Anesthetics, Local; Animals; Blister; Calmodulin; Dermatologic Agents; Dise | 2000 |
Animal models for tardive dyskinesia: effects of thioridazine.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Homovanillic A | 1977 |
The pathophysiology of tardive dyskinesia.
Topics: Animals; Antipsychotic Agents; Apomorphine; Behavior, Animal; Chlorpromazine; Corpus Striatum; Disea | 1985 |